DaTSCAN™ (Ioflupane ¹²³I)

DaTSCAN™ (Ioflupane ¹²³I injection) is a radiopharmaceutical indicated for striatal dopamine transporter (DaT) visualization using single-photon emission computed tomography (SPECT) brain imaging in adult patients with clinically uncertain Parkisonian syndromes (CUPS) and it also helps to differentiate dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD).

Adverse events reporting

Adverse events should be reported
Reporting forms and information can be found at: http://www.mhra.gov.uk/yellowcard
Adverse events should also be reported to GE HealthCare at:
GPV.drugsafety@gehealtcare.com

At a glance

Pioneer and leader in DaT SPECT imaging

A pioneer and leader in DaT SPECT imaging, supported by more than two decades of data demonstrating clinical value that may aid in diagnosis.^3-6

Visualisation & Quantification

DaTQUANT can bring objectivity and enhance confidence in DaTSCAN image assessment.

Proven operational excellence

With over 20 years of experience in manufacturing and distributing DaTSCAN, we have established a reliable global supply chain.¹

Commited to support Neuroimaging community

Continually investment in R&D, discussions at key Neurology conferences with symposia, webinars.

Confidence in the vial and far beyond

DaTSCAN (loflupane 123I ) is a radiopharmaceutical used in a brain scan (SPECT) to visualize striatal dopamine transporters assisting in the evaluation of patients with Clinically Uncertain Parkinsonian Syndromes (CUPS) and patient with Probable Dementia with Lewy Body(DLB). DaTSCAN does not replace the physician's clinical diagnosis, but may help support the clinical evaluation and diagnostic confidence.

Confidence in Numbers

20+

years in EU

>1.3 M

DaTSCAN scans have been performed¹

4 min

a patient is scanned every 3.5 min worldwide⁷

98%

Of the vials were successfully delivered on time from our Eindhoven site in 2022 and 2023.¹

Download DaTQUANT 2.0 for PC

Test drive DaTQUANT 2.0

Prior to purchase, test drive DaTQUANT 2.0 by downloading, installing and processing the included example studies. Import and processing of site data requires purchase of a license for DaTQUANT 2.0.

Visit DaTQUANT website >

To purchase DaTQUANT 2.0
To purchase a license for DaTQUANT 2.0, please click below on the contact us button to get in touch with your account manager.

Contact Us >

BENEFITS

Find out about our UK back-up reporting service

DaTSCAN images are visually read and are generally easy to interpret. Occasionally, you may find difficulty in interpreting an image. If you are in any doubt with image interpretation, we can provide a support service.
GE HealthCare offers a DaTSCAN Back-Up Reporting Service. The service is offered for DaTSCAN images where you have difficulty with interpretation. The image is reviewed by an experienced independent Nuclear Physician who provides a second opinion on the DaTSCAN image. Please note, there is a charge for this service.
To find out more about obtaining a back-up report, please email backup.reportUKI@ge.com

DIAGNOSTIC CLARITY

Quantitative analysis of DaTSCAN (Ioflupane ¹²³I) images at your fingertips

The DaTQUANT Software application enables visual evaluation and quantification of Ioflupane ¹²³I (DaTSCAN) images. Learn more how this application may assist in your evaluation of patients with a suspected Parkinsonian Syndrome and Dementia with Lewy Body (DLB).

Learn more

OPERATIONAL EXCELLENCE

Precise supply chain from dose to delivery

• In Eindhoven, DaTSCAN production capacity has increased by 12% over the past five years.¹
• In Eindhoven, we continue to invest in the coming years to continue to serve the neurology market.¹

REFERENCES

1. Data on file. GE HealthCare. Supply chain data 2023
2. Booij J et al. J Nuc Med 2017,58: 1821-6
3. Catafau AM, et al. Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord. 2004 Apr 22; 19(10): 1175-1182.
4. Kupsch AR, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosurg Psychiatry. 2012 Apr 6; 83(6): 620-628.
5. Bajaj N, et al. Association between Hoehn and Yahr, mini-mental state examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes. Alzheimers Res Ther. 2014 Oct 8; 6(5-8): 67.
6.Bega D et al. NPJ Parkinsons Dis 2021; 7(1): 43.
7.GE HealthCare, patient Impact Letter, February 2024

JB03105UK